ERBB2 and breast carcinoma: The study of Zong HF et al. constructed a HER2/HER3-targeting bsADC (DAR 2.89) and displayed high selectivity and better internalization, which suppressed breast cancer cells in vitro with a comparable efficacy of HER2- and HER3-monospecific ADC combined injection [93].